Mora Amat

533 total citations
22 papers, 335 citations indexed

About

Mora Amat is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Mora Amat has authored 22 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Cancer Research and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Mora Amat's work include Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (5 papers) and CAR-T cell therapy research (3 papers). Mora Amat is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (5 papers) and CAR-T cell therapy research (3 papers). Mora Amat collaborates with scholars based in Argentina, Spain and United States. Mora Amat's co-authors include José Mordoh, Estrella Mariel Levy, Juan Martín Arriaga, Michele Bianchini, María P. Roberti, Yamila Rocca, Luisina Bruno, Eduardo Huertas, Alejandro Pairola and Fernando Sánchez Loria and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Mora Amat

18 papers receiving 333 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mora Amat Argentina 9 193 179 55 43 36 22 335
Alejandro Pairola Argentina 5 141 0.7× 159 0.9× 44 0.8× 20 0.5× 20 0.6× 7 265
Eduardo Huertas Argentina 9 208 1.1× 159 0.9× 50 0.9× 27 0.6× 57 1.6× 19 390
Yamila Rocca Argentina 8 224 1.2× 296 1.7× 49 0.9× 20 0.5× 15 0.4× 9 384
Fernando Sánchez Loria Argentina 10 164 0.8× 159 0.9× 48 0.9× 55 1.3× 45 1.3× 20 390
Yoshinari Atarashi Japan 8 99 0.5× 152 0.8× 179 3.3× 59 1.4× 23 0.6× 14 333
Jane Straus United States 7 182 0.9× 232 1.3× 111 2.0× 28 0.7× 145 4.0× 8 356
Guifang Ouyang China 10 63 0.3× 46 0.3× 152 2.8× 76 1.8× 32 0.9× 42 276
Joanne Yap Australia 10 70 0.4× 272 1.5× 69 1.3× 45 1.0× 19 0.5× 15 404
Ming Zheng United States 7 110 0.6× 37 0.2× 96 1.7× 59 1.4× 59 1.6× 8 294
Soo Young Hwang United States 9 52 0.3× 63 0.4× 101 1.8× 28 0.7× 44 1.2× 31 298

Countries citing papers authored by Mora Amat

Since Specialization
Citations

This map shows the geographic impact of Mora Amat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mora Amat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mora Amat more than expected).

Fields of papers citing papers by Mora Amat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mora Amat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mora Amat. The network helps show where Mora Amat may publish in the future.

Co-authorship network of co-authors of Mora Amat

This figure shows the co-authorship network connecting the top 25 collaborators of Mora Amat. A scholar is included among the top collaborators of Mora Amat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mora Amat. Mora Amat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Nadal, Jorge, et al.. (2024). The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review. Cancers. 16(2). 396–396. 9 indexed citations
3.
Enrico, Diego, et al.. (2024). Higher risk of recurrence in early-stage breast cancer patients with increased levels of ribosomal protein S6. Scientific Reports. 14(1). 25136–25136. 1 indexed citations
4.
Enrico, Diego, et al.. (2023). Generalized Lymphatic Anomaly as a Differential Diagnosis of Lytic Lesions. SHILAP Revista de lepidopterología. 16(1). 597–603.
5.
Enrico, Diego, Andrés Rodríguez, Luisina Bruno, et al.. (2023). Atypical pattern of response in rectal cancer after neoadjuvant pembrolizumab treatment: a case report, literature review, and proposed management model. Journal of Gastrointestinal Oncology. 14(3). 1635–1642. 2 indexed citations
6.
Amat, Mora, et al.. (2023). A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Gu閞in in patients with non-muscle invasive bladder carcinoma: A retrospective study. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 31(2). 207–220. 7 indexed citations
7.
Ángel, Martín, et al.. (2023). Enhancing Clinical Decision-Making in LATAM through Virtual Genitourinary Tumour Boards. SHILAP Revista de lepidopterología. 4(6). 454–457.
8.
O’Connor, Juan Manuel, Eduardo Huertas, Fernando Sánchez Loria, et al.. (2022). Implementation of a virtual multicenter gastrointestinal tumor board to reduce cancer disparities in Argentina. World Journal of Clinical Oncology. 13(6). 423–428. 8 indexed citations
9.
Ángel, Martín, et al.. (2022). Desmoid tumour in an inguinal hernia in a patient with a previous diagnosis of melanoma. ecancermedicalscience. 16. 1394–1394.
10.
Enrico, Diego, Luisina Bruno, Mora Amat, et al.. (2022). CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression.. Journal of Clinical Oncology. 40(16_suppl). 1056–1056. 9 indexed citations
11.
12.
García-Ruiz, Alonso, Juan Martín-Liberal, Cinta Hierro, et al.. (2018). Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability. Annals of Oncology. 29. viii653–viii653. 5 indexed citations
13.
Martín-Liberal, Juan, Francesca Pagliuca, Cinta Hierro, et al.. (2018). Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT). Annals of Oncology. 29. viii45–viii45. 1 indexed citations
14.
15.
Rizzo, Manglio, et al.. (2017). High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers. Journal of Breast Cancer. 20(2). 170–170. 8 indexed citations
16.
Roberti, María P., Yamila Rocca, Mora Amat, et al.. (2012). IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. Breast Cancer Research and Treatment. 136(3). 659–671. 48 indexed citations
17.
Rocca, Yamila, María P. Roberti, Juan Martín Arriaga, et al.. (2012). Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immunity. 19(1). 76–85. 116 indexed citations
18.
Arriaga, Juan Martín, Estrella Mariel Levy, Alicia Bravo, et al.. (2011). Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival. Human Pathology. 43(2). 197–208. 43 indexed citations
19.
Szyldergemajn, Sergio, Juan Manuel O’Connor, Guillermo Méndez, et al.. (2005). Neuroendocrine tumors of the gastroenteropancreatic system (NET-GEP). Correlation between Ki-67 immunostaining, histological features and clinical behaviour. Journal of Clinical Oncology. 23(16_suppl). 4192–4192. 1 indexed citations
20.
Grau, Juan J., Joan Carles, Mariano Monzó, et al.. (2004). Expression of cyclooxygenase-2 mRNA (COX2-mRNA) in peripheral blood (PB) of head and neck cancer patients (HNC) and healthy controls (HC). Journal of Clinical Oncology. 22(14_suppl). 5521–5521. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alejandro Pairola Breakdown of academic impact, for papers by Eduardo Huertas Breakdown of academic impact, for papers by Yamila Rocca Breakdown of academic impact, for papers by Fernando Sánchez Loria Breakdown of academic impact, for papers by Yoshinari Atarashi Breakdown of academic impact, for papers by Jane Straus Breakdown of academic impact, for papers by Guifang Ouyang Breakdown of academic impact, for papers by Joanne Yap Breakdown of academic impact, for papers by Ming Zheng Breakdown of academic impact, for papers by Soo Young Hwang
Rankless by CCL
2026